Clinigen Extends Exclusive European Clinical Trial Sourcing and Supply Agreement with Accord Healthcare
First of its kind, ‘on demand’ supply service for clinical trials to be offered
Burton-on-Trent, England, January 10, 2019 / B3C newswire / -- Clinigen Group plc (AIM: CLIN, ‘Clinigen’), the global pharmaceutical and services company, announces that its Clinical Trial Service (‘CTS’) business has extended its exclusive European clinical trial supply agreement with Accord Healthcare (‘Accord’). Clinigen is also offering pharma companies an ‘on demand’ service to Accord’s products, a first for the industry.
Clinigen and Accord have been partnered since 2012 to deliver oncology Injectable Products, including carboplatin, cisplatin and paclitaxel, into clinical trials. The extended agreement now covers Accord’s European Solid Dose Products, including those in the central nervous system, autoimmune, diabetes and anti-viral therapy areas.
The CTS team is the sole point of contact for all clinical trial supply enquiries, ensuring an effective and secure supply chain in the distribution of Accord’s European product portfolio to pharmaceutical manufacturers, contract research organisations (CROs), clinical trial contract packagers and other specialist service providers. The drugs are supplied for use as comparator, co-therapy, rescue and adjunctive drugs in clinical trials.
The ‘on demand’ supply service will be available for any Clinigen client running clinical trials. They will be offered instant access to key products from Accord's generic oncology Injectable Product portfolio. Products will be held in large batch sizes on consignment ready for instant dispatch to new and existing clinical trials.
This is the first type of dedicated service providing instant access to products solely for clinical trials in the industry and directly tackles the constant timeline and flexibility challenges experienced when running clinical trials.
Shaun Chilton, Group Chief Executive Officer of Clinigen, said: “This extended agreement builds on the strong partnership we have with Accord in providing access to its medicines for use in clinical trials.
“The launch of our ‘on demand’ offering demonstrates the ability we have across the Group and the specialisms we have in the supply and distribution of medicines. These capabilities enable us to provide the best possible service to those running clinical trials.”
Phill Semmens, Senior Vice President Commercial, Accord Healthcare, EMENA, said: “We are delighted that the strong collaboration Accord and Clinigen have built over the past six years continues to expand with the agreement to include solid dose oral products.
“The scope of this partnership is a first for the industry, allowing us to ensure that our products are available as comparators in a variety of vital clinical trials, helping to further medical knowledge and the identification of new treatment options to improve patient care.”
About Clinigen Group
Clinigen Group plc (AIM: CLIN) is a global pharmaceutical and services company with a unique combination of businesses focused on providing ethical access to medicines. Its mission is to deliver the right medicine to the right patient at the right time through three areas of global medicine supply; clinical trial, unlicensed and licensed medicines.
About Accord Healthcare
Headquartered in the United Kingdom (UK), Accord Healthcare Europe is one of the fastest growing generic pharmaceutical companies in Europe. Accord has an extensive supply chain through its four UK based sites, helping to ensure a consistent supply of life-enhancing medicines for patients, whilst supporting customers to react quickly to dynamic market conditions.
Clinigen Group plc
Shaun Chilton, Group Chief Executive Officer
Matt Parrish, Head of Investor Relations
+44 (0) 1283 495010
Melanie Toyne-Sewell / Alex Shaw / Deborah Bell
+44 (0) 20 7457 2020
Published by B3C newswire and shared through Newronic®